Download
Company intelligence · Prepared from public filings
Grey Wolf Therapeutics Limited
ACTIVENo. 10989365Incorporated 29 Sept 2017Abingdonimmuno-oncology therapeutics
Register data as of 27 Aug 2026
69 filings read · view all sources ↓
Watch this company69 filings read · view all sources ↓
Raised, filed rounds
£69.8m
Priced rounds
1
Peak step-up
–
Peak implied valuation
£69.8m
Last allotment
Nov 2017
Exhibit 2
Funding rounds, as filed
| Allotted | Share class | Price / share | Raised | Implied post-money | Step vs prior | Source |
|---|---|---|---|---|---|---|
| 16 Nov 2017 | Ordinary | £59.99 | £69.8m | £69.8m | first | SH01 ↗ |
| Total, 1 priced rounds | £69.8m | |||||
Source: Companies House filing history, company 10989365. Every row links to the filed document it was read from. Prices and share counts as filed; implied post-money is price per share times shares in issue after the allotment.
Methodology
Notes. Raised is the sum of shares allotted times price per share across priced allotments filed on form SH01. Peak step-up is the highest price per share divided by the first priced round. Implied post-money is price per share times shares in issue after the allotment: an approximation that ignores class rights and unexercised options. Allotments classified as option-scheme or nominal issues are excluded from the trajectory.Primary documents
Every figure on this page is read from a document filed at Companies House and links to it. The full record is public: filing history of Grey Wolf Therapeutics Limited at Companies House ↗. Tero retains an archived copy of each parsed filing. Information, not investment advice.